6.34
Schlusskurs vom Vortag:
$6.10
Offen:
$6.08
24-Stunden-Volumen:
115.03K
Relative Volume:
0.90
Marktkapitalisierung:
$353.40M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-2.7094
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
+9.31%
1M Leistung:
+34.32%
6M Leistung:
+45.08%
1J Leistung:
+0.79%
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
FHTX
Foghorn Therapeutics Inc
|
6.34 | 323.30M | 34.16M | -98.43M | -119.33M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
2024-09-03 | Eingeleitet | Jefferies | Buy |
2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
2023-03-28 | Eingeleitet | BofA Securities | Buy |
2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
2020-11-17 | Eingeleitet | Cowen | Outperform |
2020-11-17 | Eingeleitet | Goldman | Buy |
2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com
Foghorn Therapeutics Inc. Stock Analysis and ForecastBreakout stock performance - Autocar Professional
What analysts say about Foghorn Therapeutics Inc. stockAccelerated capital growth - jammulinksnews.com
Is Foghorn Therapeutics Inc. a good long term investmentFree Stock Market Trend Analysis - jammulinksnews.com
What drives Foghorn Therapeutics Inc. stock pricePhenomenal capital appreciation - jammulinksnews.com
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.5% – What’s Next? - Defense World
Why Foghorn Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
SAIL Stock Analysis and ForecastFree Trading Psychology Coaching - Jammu Links News
What analysts say about Leonardo DRS Inc. stockMarket-beating performance - Jammu Links News
What makes Foghorn Therapeutics Inc. stock price move sharplyHigh Potential Safe Trades - Newser
How Foghorn Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser
(FHTX) Trading Report - news.stocktradersdaily.com
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon - simplywall.st
(FHTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
Foghorn Therapeutics Signs New Lease Agreement - TipRanks
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Exchange Traded Concepts LLC Grows Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
When the Price of (FHTX) Talks, People Listen - news.stocktradersdaily.com
Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks
Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World
BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World
Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire
10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):